PG | Weekly | Haru Insights

Procter & Gamble’s $3.8 billion acquisition of Thorne HealthTech represents a pivotal strategic realignment, marking its most aggressive move into the science-backed wellness sector and signaling a break from its legacy consumer staples model.
The wide valuation divergence—$201.56 vs. $107.52—underscores intense market skepticism, with the outcome now heavily dependent on PG’s ability to execute margin improvements and deliver tangible returns from its M&A strategy.

PG’s acquisition of Thorne HealthTech is a bold, transformative bet on the future of preventive health, proving the company is finally acting with urgency to reinvigorate growth beyond declining core categories.
Its 70-year dividend growth streak remains a rare and defining strength, demonstrating unshakable financial discipline and trustworthiness in an era of erratic corporate behavior.
The Thorne deal injects a much-needed innovation catalyst into PG’s portfolio, shifting perception from stagnant giant to a proactive player in high-margin wellness.
Acquiring a premium brand with clinical credibility strengthens PG’s credibility in science-forward markets, potentially unlocking new consumer trust and margins.
The move signals PG is willing to disrupt its own legacy, a necessary and courageous pivot that could unlock long-term value if execution matches ambition.

The Procter & Gamble Company (PG)[Tv]